Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program ...
The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...
Johnson & Johnson has filed a lawsuit seeking validation of its rebate model for 340B drugs, which offers post-sale rebates instead of upfront discounts. The initiative, criticized by hospitals and ...
Eli Lilly contends it should be allowed to vet data from 340B hospitals before providing rebates, rather than offer upfront ...
Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...
Lilly filed a lawsuit Nov. 14 against HHS head Xavier Becerra and the Health Resources and Services Administration for blocking a plan to change its 340B program from immediate discounts to offering ...
Eli Lilly (LLY) files lawsuit against U.S. health agency over 340B Program rebates, alleging arbitrary blockage of its cash ...
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on ...
Eli Lilly said on Thursday it sued the federal Health Resources and Services Administration (HRSA) over allegedly blocking ...
Eli Lilly is now the second drugmaker to propose a rebate model for 340B drug price discounts — and the second to ...
Drugmaker Johnson and Johnson is suing the Department of Health and Human Services and the Health Resources and Services Administration for blocking its new 340B rebate model, and is seeking to verify ...
The aims of the 340B program are important. But, unfortunately, there is little evidence that the program is delivering on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback